日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers

Nanrilkefusp alfa (SOT101) 是一种 IL-15 受体 βγ 超激动剂,可作为单药或与抗 PD-1 药物联合用于治疗晚期癌症患者。

Stephane Champiat ,Elena Garralda ,Vladimir Galvao ,Philippe A Cassier ,Carlos Gomez-Roca ,Iphigenie Korakis ,Peter Grell ,Aung Naing ,Patricia LoRusso ,Romana Mikyskova ,Nada Podzimkova ,Milan Reinis ,Kaissa Ouali ,Andreu Schoenenberger ,Joachim Kiemle-Kallee ,Sascha Tillmanns ,Richard Sachse ,Ulrich Moebius ,Radek Spisek ,David Bechard ,Lenka Palova Jelinkova ,Irena Adkins ,Aurelien Marabelle

Genome instability and crosstalk with the immune response

基因组不稳定性及其与免疫反应的相互作用

Chabanon, Roman M; Danlos, François-Xavier; Ouali, Kaissa; Postel-Vinay, Sophie

Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023

2008年至2023年血液系统恶性肿瘤患者参与早期临床试验的相关性、风险和益处

Guerra, Matteo; Alouani, Emily; Hueso, Thomas; Ouali, Kaissa; Danu, Alina; Hollebecque, Antoine; Bahleda, Rastislav; Willekens, Christophe; Gazzah, Anas; Baldini, Capucine; Postel-Vinay, Sophie; Micol, Jean-Baptiste; Massard, Christophe; De Botton, Stéphane; Ribrag, Vincent; Michot, Jean-Marie

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

ANV419治疗复发/难治性晚期实体瘤患者的I期首次人体剂量递增研究

Mathiot, Laurent; Combarel, David; Cagnat, Justin; Delahousse, Julia; Ouali, Kaissa; Marabelle, Aurelien; Loriot, Yohann; Ponce, Santiago; Champiat, Stephane; Broutin, Sophie; Danlos, Francois-Xavier

The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases

多学科讨论(MDD)在纤维化间质性肺疾病诊断和治疗中的作用

Ageely, Ghofran; Souza, Carolina; De Boer, Kaissa; Zahra, Saly; Gomes, Marcio; Voduc, Nha